Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Accounts Payables: 2010-2025

Historic Accounts Payables for Heron Therapeutics (HRTX) over the last 13 years, with Sep 2025 value amounting to $12.0 million.

  • Heron Therapeutics' Accounts Payables rose 17.95% to $12.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.0 million, marking a year-over-year increase of 17.95%. This contributed to the annual value of $11.7 million for FY2024, which is 261.39% up from last year.
  • As of Q3 2025, Heron Therapeutics' Accounts Payables stood at $12.0 million, which was down 0.17% from $12.0 million recorded in Q2 2025.
  • Heron Therapeutics' Accounts Payables' 5-year high stood at $13.8 million during Q2 2022, with a 5-year trough of $837,000 in Q1 2024.
  • For the 3-year period, Heron Therapeutics' Accounts Payables averaged around $7.3 million, with its median value being $10.2 million (2024).
  • Per our database at Business Quant, Heron Therapeutics' Accounts Payables tumbled by 85.82% in 2023 and then spiked by 1,373.48% in 2025.
  • Quarterly analysis of 5 years shows Heron Therapeutics' Accounts Payables stood at $3.8 million in 2021, then fell by 15.20% to $3.2 million in 2022, then rose by 0.47% to $3.2 million in 2023, then soared by 261.39% to $11.7 million in 2024, then rose by 17.95% to $12.0 million in 2025.
  • Its last three reported values are $12.0 million in Q3 2025, $12.0 million for Q2 2025, and $12.3 million during Q1 2025.